| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Involves the Induction of Secretory Leukocyte Protease Inhibitor1
Department of Molecular and Cellular Interactions, Vlaams Interuniversitair Instituut voor Biotechnologie, Vrije Universiteit Brussel, Brussels, Belgium
According to the cancer immunoediting concept, inflammatory mediators play not only a critical role in promoting host protection against cancer but also contribute to cancer cell growth and survival. TNF-
is a critical factor in this network. However, the mechanisms underlying the tumor-promoting effect of TNF- have not been fully elucidated yet. We previously reported that in vitro culture of Lewis lung carcinoma 3LL cells with TNF--producing macrophages resulted in enhanced resistance toward TNF--mediated lysis and increased malignancy of the 3LL cells. In this study, we analyzed the effects of endogenous TNF- on TNF- resistance and malignant behavior in vivo of low-malignant/TNF--sensitive 3LL-S cells and cancer cells derived from 3LL-S tumors that developed in wild-type or TNF-–/– mice. Interestingly, 3LL-S cells acquired a malignant phenotype in vivo depending on the presence of host TNF-, whereas acquisition of TNF- resistance was TNF--independent. This result suggested that malignancy-promoting characteristics of 3LL-S cells other than TNF- resistance are influenced in vivo by TNF-. We previously identified the malignancy-promoting genes, secretory leukocyte protease inhibitor (SLPI) and S100A4, as being up-regulated in 3LL-S cells upon their s.c. growth in wild-type mice. In this study, we show that SLPI, but not S100A4, was induced in 3LL-S cells both in vitro and in vivo by TNF-, and that silencing of in vivo induced 3LL-S SLPI expression using RNA interference abrogated in vivo progression but did not influence TNF- resistance. These data indicate that SLPI induction may be one mechanism whereby TNF- acts as an endogenous tumor promoter.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This project was supported in part by Sportvereniging Tegen Kanker, Stichting Emmanuel van der Schueren, and Krediet aan Navorsers from Fonds voor Wetenschappelijk Onderzoek. N.D. is a fellow of the Fonds voor Wetenschappelijk Onderzoek.
2 Address correspondence and reprint requests to Dr. Nick Devoogdt, Department of Molecular and Cellular Interactions, Vlaams Interuniversitair Instituut voor Biotechnologie, Vrije Universiteit Brussel, Gebouw E, niveau 8, Pleinlaan 2, 1050 Brussels, Belgium. E-mail address: ndevoogd{at}vub.ac.be
3 Abbreviations used in this paper: WT, wild type; shRNA, short-harpin RNA; d.p.i., days postinjection; DMBA, dimethylbenz(a)anthracene; TPA, 12-O-tetradecanoylphorbol-13-acetate; AU, arbitrary units.
This article has been cited by other articles:
|
|
 |
|
  F. A. Simpkins, N. M. Devoogdt, N. Rasool, N. E. Tchabo, E. U. Alejandro, M. M.R.N. Kamrava, and E. C. Kohn The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells Carcinogenesis, March 1, 2008; 29(3): 466 - 472. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
